Dynamika

IImage Analysis Group (IAG) has won an award in the Innovation category in the 2024 Pharmaceutical Technology Excellence Awards for its DYNAMIKA.

DYNAMIKA is an industry-leading platform for central image review and analysis in clinical trials.

The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the pharmaceuticals industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies that are driving change in the industry.

IAG’s platform has revolutionized imaging analytics by integrating automated workflow and artificial intelligence (AI) to enhance trial efficiency, streamline global data management, and ensure robust security measures.

DYNAMIKA is a cloud-native intelligent enterprise workflow solution brought by IAG team to simplify and modernize central data collection, quality control and central review in global clinical trials. In 2024, IAG team released DYNAMIKA V7.

With integrated workflows, DYNAMIKA reduces burden on the clinical sites, takes away manual tasks of image anonymization and quality control. It powers radiology workflows and reads, reduces readers’ time and increases reproducibility. It brings best-in-class library of AI tools to enable multiple radiology use cases. DYNAMIKA serves as a central trusted hub for image collection, secure management, and instant access. It is recently re-accredited with ISO13485 by the British Standards Institute and developed in compliance with 21 CFR part 11 standard for clinical trials.

Streamlining global trial data management and smart deployment of AI

Dynamika

Image Analysis Group is a leading imaging Clinical Research Organization, combining medical expertise, a global team and the DYNAMIKA platform with embedded AI capabilities for data management and central review. For nearly 20 years, IAG has been supporting pharma companies in developing novel drugs, using imaging to assess safety and efficacy.

IAG’s innovation extends to its cloud-based platform, which has transformed the management of global trial data. By promoting AI and automation, IAG’s team thrives to make the data management process more efficient and secure.

DYNAMIKA’s role-based workflows and cloud-native infrastructure have improved stakeholder decision-making and workload, while optimizing security features to ensure the safety of patient data and compliance with study protocols.

The platform supports all trial stakeholders through individually designed workflow and data access. It enhances site performance with digital assistance, provides project managers and sponsors with tools to oversee stakeholder performance and greatly reduced IT-related costs in trials.

DYNAMIKA’s application has had a positive effect on medical research and patient outcomes in various therapeutic areas. Notably, IAG delivers phase I-III trials in rheumatology, immunology, metabolic disease, oncology and neurosciences.

Dynamika

For drug developers, it is now possible to tackle complex questions around tumors’ pseudo-progression and patient phenotyping, as DYNAMIKA seamlessly brings state-of-the-art and advanced assessments in one platform.

IAG closely works with AI and image analysis companies to enable them to deploy their innovation within trials through DYNAMIKA’s infrastructure. As DYNAMIKA is being deployed across major therapeutic areas, it brings together the industry’s richest library of tools to assess medical images. This is particularly impactful in rare diseases, where dedicated methods to assess drug efficacy or safety may not be readily available. With DYNAMIKA, the development of drugs for rare diseases can be significantly accelerated, demonstrating the platform’s adaptability and the potential for customization.

Dr Olga Kubassova

‘It is IAG’s team vision to maintain DYNAMIKA’s ability to work across therapeutic areas and continue processing imaging data using the FDA-required and unique endpoints developed in-house and by IAG’s partners.’

– Dr Olga Kubassova, IAG’s Founder and President.

Additionally, DYNAMIKA’s ability to efficiently handle large complex datasets and AI models allowed IAG’s pharmaceutical collaborators to utilize trials’ historic data to build predictive assessment and gain additional insights into drug efficacy.

The platform’s ability to manage radiology and histology data, with plans to incorporate clinical data and data from decentralized trials, including wearable devices, further demonstrates its versatility and forward-thinking approach of the team.

‘We are delighted to receive this award as Image Analysis Group continues to raise the bar for security, compliance, and innovation in the imaging clinical trial market. This recognition acknowledges the efforts of our team who released the next-generation platform to bring true cloud-based seamless process into trials and power companies with AI and novel insights when they use imaging to investigate safety and efficacy of their novel drug candidates.’’

Roughan Sheedy, CEO, Image Analysis Group

Company Profile

IAG is a leading imaging clinical research organization that combines medical and operational expertise with proprietary cloud-based platform DYNAMIKA for data management, central review and AI insights in trials that require medical imaging to assess safety or efficacy of novel drug candidates.

IAG has been serving biotech and pharma clients globally since 2007, reliably supporting all aspects of phase I to III imaging trials across multiple indications. Working with clinical operations, translational and medical affairs team, IAG pioneers effective deployment of AI to maximize value of trial data, enhance the value and market potential of novel therapeutic assets, reduce risks of R&D and strategic investments, as demonstrated through successful pharmaceutical partnerships.

Contact Details

E-mail Dr Olga Kubassova, President: imaging.experts@ia-grp.com

Links

Website: www.ia-grp.com